114 related articles for article (PubMed ID: 22520336)
1. Metastatic breast cancer: we do need primary cost data.
Bonastre J; Jan P; Barthe Y; Koscielny S
Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
[TBL] [Abstract][Full Text] [Related]
2. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
3. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
4. [Macro-economic calculation of spending versus micro-economic follow-up of costs of breast cancer].
Borella L; Paraponaris A
Rev Epidemiol Sante Publique; 2002 Dec; 50(6):581-92. PubMed ID: 12515928
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
6. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
7. [Cost effectiveness evaluation of breast cancer therapy. Comparative analysis 1975-1985 in a cancer prevention center].
Lapeyre-Mestre M; Daly-Schveitzer N; Boussin G; Delande G
Rev Epidemiol Sante Publique; 1993; 41(5):397-406. PubMed ID: 8284480
[TBL] [Abstract][Full Text] [Related]
8. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
9. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach.
Hanly P; Timmons A; Walsh PM; Sharp L
Value Health; 2012 May; 15(3):429-36. PubMed ID: 22583452
[TBL] [Abstract][Full Text] [Related]
10. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
11. [Advanced breast cancer: an evaluation of the cost of recurrence].
Bercez C; Lebrun T; Bonneterre ME; Selke B; Lenne X; Bonneterre J
Bull Cancer; 1999 Jun; 86(6):585-90. PubMed ID: 10417432
[TBL] [Abstract][Full Text] [Related]
12. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Raaijmakers JA; Schellens JH
Breast Cancer Res Treat; 2013 Jun; 139(2):489-95. PubMed ID: 23645005
[TBL] [Abstract][Full Text] [Related]
14. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
Lamerato L; Havstad S; Gandhi S; Jones D; Nathanson D
Cancer; 2006 May; 106(9):1875-82. PubMed ID: 16572409
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
16. Health care costs for treatment of disseminated breast cancer.
Dahlberg L; Lundkvist J; Lindman H
Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a short stay admission programme for breast cancer surgery.
de Kok M; Dirksen CD; Kessels AG; van der Weijden T; van de Velde CJ; Roukema JA; Bell AV; van der Ent FW; von Meyenfeldt MF
Acta Oncol; 2010 Apr; 49(3):338-46. PubMed ID: 20397768
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
19. Metastatic non-small cell lung cancer: costs associated with disease progression.
Fox KM; Brooks JM; Kim J
Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of cancer treatment costs: another tool for oncology managers.
Chirikos TN; Ruckdeschel JC; Krischer JP
J Oncol Manag; 2001; 10(3):11-7. PubMed ID: 11548179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
